Predicting future glaucoma candidates

Article

Combined analysis of two clinical glaucoma trials, presented at the American Academy of Ophthalmology annual meeting, suggests that it would be beneficial for ophthalmologists to use a five-year risk assessment model to better predict which patients have an increased risk of developing glaucoma.

Combined analysis of two clinical glaucoma trials, presented at the American Academy of Ophthalmology annual meeting, suggests that it would be beneficial for ophthalmologists to use a five-year risk assessment model to better predict which patients have an increased risk of developing glaucoma.

In 2005, Robert Weinreb, MD and Filipe Medeiros, MD, constructed a risk assessment model based on findings from the 2002 Ocular Hypertension Treatment Study (OHTS). This study found that early intervention with IOP lowering medications could prevent glaucoma in at-risk patients. The OHTS prediction model was then tested on patients in the placebo group of the European Glaucoma Prevention Study (EGPS), a study that enrolled a total of 1081 subjects at 18 European centres to receive either dorzolamide or placebo. The OHTS arm of the study examined 819 subjects with a median follow-up of every six months for 6.6 years. The EGPS placebo group examined 500 subjects with a median follow-up of every six months for 4.8 years. The two study samples were pooled to increase the precision of a five-year predictive model for the development of POAG.

Analysis of the results found that subjects with elevated IOP along with other risk factors such as age (40 years old +), are at the highest risk of developing POAG. The researchers believe that the five-year risk assessment model will dramatically help reduce the number of subjects going on to development this disease.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.